Daily Archives: June 10, 2020

Taconic Biosciences Expands Production of Critical Immunodeficient Model

Local Production of the CIEA NOG mouse® Model Now Available on the West Coast

RENSSELAER, N.Y., June 10, 2020 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces local West Coast United States production of the immunodeficient CIEA NOG mouse® model.

Immunodeficient animal models are critical to the drug discovery ecosystem.  One of the most common contributors to the high product attrition rate for this industry is difficulty recapitulating the human biosystem in an animal model.  Immunodeficient models bridge this gap by enabling foreign tissue to interact with the animal, without rejection by that animals’ immune system.  Better replication of the human body in mice is a driving force in many revolutionary medical advances, including immuno-oncology and personalized medicine.

The CIEA NOG mouse® lacks the T, B, and natural killer (NK) cells that drive immune response. It is one of the most widely used severely immunocompromised mouse models.  The NOG mouse provides the foundation for Taconic’s extensive specialized models portfolio, which includes a variety of models with specific genetic and tissue modifications for greater precision.

West Coast production addresses the thriving California biomedical community with additional flexibility in planning experiments through multiple weekly deliveries, flexible ordering timelines, and reduced transit times for the animals.  NOG mice from this site are also available at Taconic’s EF health standard, a more restrictive health standard, valuable for immunodeficient models.

“Expanding the production of such a critical resource underscores Taconic’s commitment to providing researchers with easy access to the best animal model solutions,” commented Dr. Michael Seiler, vice president of commercial products at Taconic.  “The CIEA NOG mouse® is one of the most important animal models in the world because it is the foundation of a portfolio aimed at better replicating the human biosystem in an animal model.”

To learn more about the CIEA NOG mouse® or the NOG portfolio, please contact Taconic at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:

Kelly Owen Grover

Director of Marketing Communications

(518) 697-3824

kelly.grover@taconic.com

Taconic Biosciences Expands Production of Critical Immunodeficient Model

Local Production of the CIEA NOG mouse® Model Now Available on the West Coast

RENSSELAER, N.Y., June 10, 2020 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces local West Coast United States production of the immunodeficient CIEA NOG mouse® model.

Immunodeficient animal models are critical to the drug discovery ecosystem.  One of the most common contributors to the high product attrition rate for this industry is difficulty recapitulating the human biosystem in an animal model.  Immunodeficient models bridge this gap by enabling foreign tissue to interact with the animal, without rejection by that animals’ immune system.  Better replication of the human body in mice is a driving force in many revolutionary medical advances, including immuno-oncology and personalized medicine.

The CIEA NOG mouse® lacks the T, B, and natural killer (NK) cells that drive immune response. It is one of the most widely used severely immunocompromised mouse models.  The NOG mouse provides the foundation for Taconic’s extensive specialized models portfolio, which includes a variety of models with specific genetic and tissue modifications for greater precision.

West Coast production addresses the thriving California biomedical community with additional flexibility in planning experiments through multiple weekly deliveries, flexible ordering timelines, and reduced transit times for the animals.  NOG mice from this site are also available at Taconic’s EF health standard, a more restrictive health standard, valuable for immunodeficient models.

“Expanding the production of such a critical resource underscores Taconic’s commitment to providing researchers with easy access to the best animal model solutions,” commented Dr. Michael Seiler, vice president of commercial products at Taconic.  “The CIEA NOG mouse® is one of the most important animal models in the world because it is the foundation of a portfolio aimed at better replicating the human biosystem in an animal model.”

To learn more about the CIEA NOG mouse® or the NOG portfolio, please contact Taconic at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:

Kelly Owen Grover

Director of Marketing Communications

(518) 697-3824

kelly.grover@taconic.com

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund

Lugano, Switzerland, June 10, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces that Helsinn is supporting Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund, with a donation of US$100,000.

The COVID Impacts Cancer campaign is an emergency initiative powered by Conquer Cancer and was created to support cancer patients, oncologists, and their care teams by providing educational resources and information to help patients continue to receive high-quality care throughout, and in the aftermath, of the COVID-19 pandemic.

In addition, the campaign will help fund the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) which aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The ASCO Registry is designed to collect both baseline and follow-up data on how the virus impacts cancer care and cancer patient outcomes during the COVID-19 pandemic and into 2021.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, and Board Member of Conquer Cancer, commented: “We are pleased to support Conquer Cancer’s COVID Impacts Cancer fund, a great initiative, which will benefit cancer patients and oncologists during these unprecedented times. The work Conquer Cancer are doing to help the whole cancer community is vital and the ASCO Registry, in particular, will be invaluable to help physicians learn about the impact of COVID-19 on cancer patients and ensure we are well placed to protect these vulnerable patients should any future pandemics occur.”

“Helsinn has long been dedicated to conquering cancer by supporting research,” said Nancy R. Daly, MS, MPH, Chief Executive Officer, Conquer Cancer. “We are grateful for the generous gift to the COVID Impacts Cancer fund, which is providing important resources for everyone impacted by cancer and equipping doctors with the vital information they need to care for patients everywhere.”

About the Helsinn Group

Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through in-licensing and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.

Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do which is reinforced in the company’s strategic plan by a commitment to sustainable growth.

To learn more about Helsinn Group please visit www.helsinn.com

About Conquer Cancer

Conquer Cancer®, the ASCO Foundation funds research into every facet of cancer to benefit every patient, everywhere. In 1964, seven oncologists created the American Society of Clinical Oncology (ASCO), now a global network of nearly 45,000 cancer professionals. As ASCO’s foundation, Conquer Cancer helps turn science into a sigh of relief for patients around the world by supporting groundbreaking research and education across cancer’s full continuum.

For more information, visit CONQUER.ORG

For more information:

Helsinn Group Media Contact:

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Email: Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund

Lugano, Switzerland, June 10, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces that Helsinn is supporting Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund, with a donation of US$100,000.

The COVID Impacts Cancer campaign is an emergency initiative powered by Conquer Cancer and was created to support cancer patients, oncologists, and their care teams by providing educational resources and information to help patients continue to receive high-quality care throughout, and in the aftermath, of the COVID-19 pandemic.

In addition, the campaign will help fund the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) which aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The ASCO Registry is designed to collect both baseline and follow-up data on how the virus impacts cancer care and cancer patient outcomes during the COVID-19 pandemic and into 2021.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, and Board Member of Conquer Cancer, commented: “We are pleased to support Conquer Cancer’s COVID Impacts Cancer fund, a great initiative, which will benefit cancer patients and oncologists during these unprecedented times. The work Conquer Cancer are doing to help the whole cancer community is vital and the ASCO Registry, in particular, will be invaluable to help physicians learn about the impact of COVID-19 on cancer patients and ensure we are well placed to protect these vulnerable patients should any future pandemics occur.”

“Helsinn has long been dedicated to conquering cancer by supporting research,” said Nancy R. Daly, MS, MPH, Chief Executive Officer, Conquer Cancer. “We are grateful for the generous gift to the COVID Impacts Cancer fund, which is providing important resources for everyone impacted by cancer and equipping doctors with the vital information they need to care for patients everywhere.”

About the Helsinn Group

Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through in-licensing and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.

Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do which is reinforced in the company’s strategic plan by a commitment to sustainable growth.

To learn more about Helsinn Group please visit www.helsinn.com

About Conquer Cancer

Conquer Cancer®, the ASCO Foundation funds research into every facet of cancer to benefit every patient, everywhere. In 1964, seven oncologists created the American Society of Clinical Oncology (ASCO), now a global network of nearly 45,000 cancer professionals. As ASCO’s foundation, Conquer Cancer helps turn science into a sigh of relief for patients around the world by supporting groundbreaking research and education across cancer’s full continuum.

For more information, visit CONQUER.ORG

For more information:

Helsinn Group Media Contact:

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Email: Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo

ข้อมูลโมเดลพรีคลินิก NAFLD/NASH ใหม่ที่จะนำเสนอที่ ADA 2020

ซานดิเอโก, June 10, 2020 (GLOBE NEWSWIRE) — Crown Bioscience วันนี้ได้ประกาศการนำเสนอข้อมูลการพัฒนาโมเดลพรีคลินิก NAFLD/NASH ที่เป็นกรรมสิทธิ์ใหม่ ข้อมูลจะมีให้บริการที่การประชุมทางวิทยาศาสตร์ครั้งที่ 80 จากสมาคมโรคเบาหวานแห่งอเมริกา (ADA) รวมทั้งที่อีเว้นท์เสมือนจริงโดยไม่มีค่าใช้จ่ายของ CrownBio

ข้อมูลใหม่เป็นการพัฒนาร่วมกันระหว่างโมเดล NAFLD/NASH ที่เกิดจากการดัดแปลงอาหารทั่วทั้งรายการของโมเดลหนูทดลองที่ดัดแปลงสูงและโมเดลพรีคิลินิก NHP ของ CrownBio โมเดลเหล่านี้จะช่วยเร่งการพัฒนายา NAFLD/NASH ในระยะพรีคลินิกที่มีประสิทธิภาพมากขึ้น ซึ่งในปัจจุบันยังขาดการรักษาโรคที่ผ่านการอนุมัติ

นอกจากโปสเตอร์ของ ADA 2020 แล้ว CrownBio ยังสนับสนุนวัน International NASH Day ที่เกิดขึ้นพร้อมกันในวันที่ 12 มิถุนายนด้วยการนำเสนอการพัฒนาโมเดล NAFLD/NASH CrownBio จะเป็นเจ้าภาพงานอีเว้นท์เสมือนจริงโดยไม่เสียค่าใช้จ่าย เพื่อให้สามารถเข้าถึงทรัพยากรเหล่านี้ได้ทั้งหมด ซึ่งสามารถลงทะเบียนได้ที่ CrownBio.com/ADA20

“เรามุ่งมั่นที่จะพัฒนาและเร่งการวิจัย NAFLD/NASH โดยการปรับปรุงแพลตฟอร์มของโมเดลพรีคลินิกที่มีการดัดแปลงสูงของเราอย่างต่อเนื่อง” Dr. Jim Wang รองประธานอาวุโสด้านโรคหัวใจและหลอดเลือดและโรคเกี่ยวกับการเผาผลาญที่ CrownBio กล่าว “เรายินดีเป็นอย่างยิ่งที่จะสามารถแบ่งปันงานวิจัยล่าสุดของเราในพื้นที่ที่มีความต้องการสูงในรูปแบบต่างๆ ของงานอีเว้นท์เสมือนจริงอันล้ำสมัยในเดือนมิถุนายนนี้”

งานอีเว้นท์ ADA เสมือนจริงของ CrownBio จัดขึ้นตั้งแต่วันที่ 12 ถึง 16 มิถุนายน ที่ CrownBio.com/ADA20 และจะอนุญาตให้มีการอภิปรายกับทีมโรคหลอดเลือดหัวใจและโรคเกี่ยวกับการเผาผลาญของ CrownBio รวมถึงการรีวิวและดาวน์โหลดแหล่งข้อมูลที่หลากหลายของโรคต่างๆ ประกอบด้วย NAFLD/NASH, โรคเบาหวาน, โรคอ้วน, โรคไตและโรคหัวใจและหลอดเลือด

เกี่ยวกับ Crown Bioscience Inc.

Crown Bioscience เป็นบริษัทในเครือ JSR Life Sciences เป็นผู้ให้บริการด้านการพัฒนาและการค้นคว้ายาระดับโลกที่ที่นำเสนอแพลตฟอร์มที่สร้างความเปลี่ยนแปลงต่อการพัฒนาด้านมะเร็งวิทยา การอักเสบ และการวิจัยโรคเกี่ยวกับการเผาผลาญขั้นสูง ด้วยผลงานที่ครอบคลุมด้านโมเดลและเครื่องมือการคาดการณ์ที่เกี่ยวข้อง Crown Bioscience จึงช่วยให้ลูกค้าสามารถนำเสนออาสาสมัครทางคลินิกที่เหนือกว่าได้ สำหรับข้อมูลเพิ่มเติมไปที่:

ช่องทางติดต่อสำหรับสื่อ:

Crown Bioscience
Jody Barbeau
pr@crownbio.com